This company is no longer active
ABIO Stock Overview
A clinical stage biopharmaceutical company, engages in the development and commercialization of targeted therapies for cardiovascular diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
ARCA biopharma, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.50 |
| 52 Week High | US$4.49 |
| 52 Week Low | US$1.56 |
| Beta | 0.89 |
| 11 Month Change | -16.67% |
| 3 Month Change | -32.43% |
| 1 Year Change | 21.95% |
| 33 Year Change | -19.87% |
| 5 Year Change | -52.11% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Companies Like ARCA biopharma (NASDAQ:ABIO) Can Afford To Invest In Growth
Apr 04
Is ARCA biopharma (NASDAQ:ABIO) In A Good Position To Deliver On Growth Plans?
Sep 24ARCA biopharma: Activist's Pressure Could Make This Into A Liquidation Play
May 03Is ARCA biopharma (NASDAQ:ABIO) In A Good Position To Deliver On Growth Plans?
Mar 18Is ARCA biopharma (NASDAQ:ABIO) In A Good Position To Deliver On Growth Plans?
Nov 27Here's Why We're Not Too Worried About ARCA biopharma's (NASDAQ:ABIO) Cash Burn Situation
Jul 15Here's Why We're Not Too Worried About ARCA biopharma's (NASDAQ:ABIO) Cash Burn Situation
Mar 30Enrollment underway in ARCA bio's mid-stage AB201 study in COVID-19
Dec 15We Think ARCA biopharma (NASDAQ:ABIO) Can Afford To Drive Business Growth
Dec 15
ARCA Biopharma wins FDA Fast Track status for experimental COVID treatment
Nov 24ARCA biopharma reports Q3 results
Nov 02Shareholder Returns
| ABIO | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -36.2% | 0.8% | 0.7% |
| 1Y | 22.0% | 15.0% | 32.2% |
Return vs Industry: ABIO exceeded the US Biotechs industry which returned 13.7% over the past year.
Return vs Market: ABIO matched the US Market which returned 21.5% over the past year.
Price Volatility
| ABIO volatility | |
|---|---|
| ABIO Average Weekly Movement | 12.9% |
| Biotechs Industry Average Movement | 9.9% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: ABIO's share price has been volatile over the past 3 months.
Volatility Over Time: ABIO's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 3 | Tom Keuer | www.arcabio.com |
ARCA biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of targeted therapies for cardiovascular diseases. Its lead product candidate is Gencaro, a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase IIb trial for the treatment of atrial fibrillation in patients with heart failure. It is developing Recombinant Nematode Anticoagulant Protein c2, a protein therapeutic that is in Phase IIb clinical trial for the treatment for COVID-19.
ARCA biopharma, Inc. Fundamentals Summary
| ABIO fundamental statistics | |
|---|---|
| Market cap | US$50.63m |
| Earnings (TTM) | -US$7.20m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-5.0x
P/E RatioIs ABIO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ABIO income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$7.20m |
| Earnings | -US$7.20m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.50 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did ABIO perform over the long term?
See historical performance and comparison